Key points are not available for this paper at this time.
Chronic graft-versus-host disease (CGVHD),* a multisystemic syndrome that develops 80–400 days after allogenic marrow transplantation, affects 25–45% of long-term survivors (1, 2). With early medical treatment using prednisone with either azathioprine and/or cyclosporine, scleroderma and joint contractures now rarely occur. Nevertheless, a small proportion of patients will eventually develop dermal thickening, joint contractures, and sicca syndrome (3), which may be resistant to therapy with standard immunosuppressive agents (4).
Socié et al. (Thu,) studied this question.